科创板上市公司独立董事提名人声明与承诺 提名人嘉和美康（北京）科技股份有限公司董事会，现提名柴健先生为嘉和 美康（北京）科技股份有限公司第五届董事会独立董事候选人，并已充分了解被 提名人职业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记 录等情况。被提名人已书面同意出任嘉和美康（北京）科技股份有限公司第五届 董事会独立董事候选人（参见该独立董事候选人声明）。提名人认为，被提名人 具备独立董事任职资格，与嘉和美康（北京）科技股份有限公司之间不存在任何 影响其独立性的关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、规 章及其他规范性文件，具有五年以上法律、经济、会计、财务、管理等履行独立 董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： （五）与上市公司及其控股股东、实际控制人或者其各自的附属企业具有重 大业务往来的人员，或者在有重大业务往来的单位及其控股股东、实际控制人单 位任职的人员； （六）为上市公司及其控股股东、实际控制人或者其各自的附属企业提供财 ...

为践行"以投资者为本"的上市公司发展理念，维护公司全体股东利益，增 强投资者信心，促进公司长远健康可持续发展，公司基于对未来发展前景的信心 和对公司价值的认可，结合自身发展战略和经营情况，于 2025 年 5 月 29 日发布 了 2025 年度"提质增效重回报"行动方案（以下简称"行动方案"）。 2025 年上半年，公司根据行动方案内容积极开展和落实相关工作，现将 2025 年上半年行动方案的主要执行进展情况报告如下： 一、聚焦主业发展，不断提升公司竞争力 2025 年，公司以市场需求为导向，聚焦降本增效与高质量发展，优化管理 层架构，整合核心职能，强化协同作战，严控成本开支，提升运营效率。同时， 以创新技术为手段，加快新技术新产品布局，在医、教、研、管、服、控等多个 层面持续发力，用 AI 引领医疗革新，重塑新质生产力，推动医院高质量发展。 1. 落实降本增效的策略，全面提升经营管理质量 为顺应医疗健康产业的发展需求，紧跟人工智能、大数据等前沿技术的快速 发展，实现企业高质量可持续发展，2025 年，公司全面推行降本增效策略。通 过加强项目精细化管理、严控市场活动等财务开支及成本，公司全面提升运营效 率与 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2025-058 嘉和美康（北京）科技股份有限公司 关于变更公司独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 嘉和美康（北京）科技股份有限公司(以下简称"公司")董事会近日收到独 立董事任宏女士的辞职报告。任宏女士拟辞去公司第五届董事会独立董事、审计 委员会委员（召集人）、薪酬与考核委员会委员职务。辞任后，任宏女士将不再 担任公司任何职务。 公司于 2025 年 8 月 27 日召开第五届董事会第二次会议，审议通过了《关于 变更公司独立董事的议案》，同意提名柴健先生为公司第五届董事会独立董事候 选人，任期自公司股东会审议通过之日起至第五届董事会任期届满之日止。 一、董事离任情况 | 姓 | | 离任时 | 原定任 | 离任 | 是否继续在 上市公司及 | 具体职 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名 | 离任职务 | 间 | 期到期 | 原因 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2025-057 嘉和美康（北京）科技股份有限公司 关于子公司股权转让暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●嘉和美康（北京）科技股份有限公司（以下简称"公司"）的控股孙公司 北京嘉和海森健康科技有限公司（以下简称"嘉和海森"）的自然人股东陈联忠、 蔡挺、崔凯拟将其分别持有的嘉和海森 11.8988%、6.3460%、2.3798%的股权转 让给公司关联人夏军。公司全资子公司北京嘉和美康信息技术有限公司（以下简 称"嘉和信息"）作为嘉和海森的控股股东，拟放弃此次股权转让的优先购买权、 跟随出售权。 ●上述股权转让同时，全资子公司嘉和信息拟将持有的嘉和海森的全部股权 无偿划转予上市公司，公司对嘉和海森由间接持股转变为直接持股。 ●本次交易构成关联交易，不构成重大资产重组。 ●本次交易实施不存在重大法律障碍。 ●本次关联交易已经公司第五届董事会第二次会议、第五届董事会审计委员 会第一次会议和第五届董事会独立董事第一次专门会议审议通 ...

嘉和美康公告，公司控股孙公司嘉和海森的自然人股东陈联忠、蔡挺、崔凯拟将其持有的嘉和海森 11.9%、6.35%、2.38%的股权分别转让给公司关联人夏军。全资子公司嘉和信息将放弃此次股权转让的 优先购买权，并拟将持有的嘉和海森58.7%的股权无偿划转予上市公司。交易完成后，公司对嘉和海森 的持股比例保持不变，由间接持股变为直接持股。此交易构成关联交易，不涉及重大资产重组，尚需提 交2025年第四次临时股东会审议。嘉和海森2025年上半年净利润为-1991.29万元。 ...

嘉和美康公告，2025年上半年营业收入2.19亿元，同比下降27.22%。归属于上市公司股东的净利润-1.16 亿元，上年同期为-2747.22万元。 ...

Group 1 - The core point of the news is that Jiahe Meikang's stock price dropped by 5.13% to 36.25 CNY per share, with a trading volume of 299 million CNY and a turnover rate of 5.77%, resulting in a total market capitalization of 4.987 billion CNY [1] - Jiahe Meikang (Beijing) Technology Co., Ltd. was established on March 3, 2006, and went public on December 14, 2021. The company specializes in the research and industrialization of medical information software [1] - The revenue composition of Jiahe Meikang includes 47.70% from self-developed software sales, 39.84% from software development and technical support services, 12.18% from external hardware and software sales, and 0.27% from other sources [1] Group 2 - From the perspective of major fund holdings, the Guoxin Guozheng Fund has one fund heavily invested in Jiahe Meikang. The Guoxin Guozheng Xinli A (001797) held 9,000 shares in the second quarter, accounting for 1.39% of the fund's net value, ranking as the fifth-largest holding [2] - The Guoxin Guozheng Xinli A (001797) was established on September 2, 2015, with a latest scale of 19.0233 million CNY. It has achieved a year-to-date return of 10.7%, ranking 5589 out of 8194 in its category, and a one-year return of 16.08%, ranking 6057 out of 7963. Since its inception, it has incurred a loss of 14.1% [2] - The fund manager of Guoxin Guozheng Xinli A (001797) is Zhang Honglei, who has been in the position for nearly 4 years. The total asset scale of the fund is 1.57 billion CNY, with the best return during his tenure being 52.22% and the worst being -13.4% [3]

Core Viewpoint - 嘉和美康's stock price has shown significant growth this year, with a year-to-date increase of 47.94% and a recent trading performance indicating continued interest from investors [1][2] Group 1: Stock Performance - As of August 22, 嘉和美康's stock price reached 36.69 yuan per share, with a market capitalization of 5.048 billion yuan [1] - The stock has experienced a 3.06% increase over the last five trading days and a 26.39% increase over the last 60 days [1] - The company has appeared on the龙虎榜 twice this year, with the most recent appearance on February 17 [1] Group 2: Financial Metrics - For the period from January to March 2025, 嘉和美康 reported a revenue of 101 million yuan, reflecting a year-on-year decrease of 17.43% [2] - The number of shareholders increased by 3.10% to 5,893, with an average of 23,347 circulating shares per shareholder, up 32.19% [2] Group 3: Company Overview - 嘉和美康 (Beijing Jiameikang Technology Co., Ltd.) was established on March 3, 2006, and went public on December 14, 2021 [1] - The company operates in the medical information software sector and is categorized under the computer-software development industry, focusing on vertical application software [1]

Investment Rating - The report maintains a "Buy" rating for the companies mentioned, indicating a positive outlook for their performance in the market [2][52]. Core Insights - The computer industry has shown strong relative performance, with a 12-month increase of 84.9%, significantly outperforming the CSI 300 index, which only increased by 26.7% [3]. - The release of the GLM-4.5V multimodal model by Zhipu AI marks a significant advancement in AI capabilities, achieving top performance in 41 multimodal benchmark tests [4][17]. - Kunlun Wanwei has launched the industry's first multimodal deep research agent, enhancing research capabilities by integrating multimodal retrieval and understanding [5][26]. - Cohere, a Canadian AI startup, completed a $500 million Series D funding round, raising its valuation to $6.8 billion, indicating strong investor confidence in enterprise-level AI solutions [6][41]. Summary by Sections 1. Computing Power Dynamics - The rental prices for computing power remain stable, with specific configurations priced at 5.73 RMB/hour for Tencent Cloud and 31.58 RMB/hour for Alibaba Cloud [16]. - Zhipu AI's GLM-4.5V model, with 106 billion total parameters, has set new records in multimodal benchmarks, showcasing its advanced capabilities in visual reasoning [17][20]. 2. AI Application Dynamics - QuillBot's weekly traffic increased by 4.44%, indicating growing user engagement [25]. - The new multimodal deep research agent from Kunlun Wanwei can process images and generate comprehensive reports, enhancing research efficiency [26][28]. 3. AI Financing Trends - Cohere's recent funding round highlights the growing interest in enterprise AI, with expectations of annual revenue exceeding $200 million by 2025 [41][42]. 4. Investment Recommendations - The report suggests focusing on companies like Jiahe Meikang, Yida Information, and Weike Technology, which are positioned for growth in the AI and robotics sectors [50][51].

证券之星消息，8月18日AI医疗板块较上一交易日上涨1.59%，塞力医疗领涨。当日上证指数报收于 3728.03，上涨0.85%。深证成指报收于11835.57，上涨1.73%。AI医疗板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 29.87 | 5.14% | 40.91万 | 11.87亿 | | 300725 | 药石科技 | 49.92 | 4.33% | 24.24万 | 11.73亿 | | 688246 | 嘉和美康 | 36.72 | 3.15% | 5.10万 | 1.85亿 | | 300168 | 万达信息 | 8.23 | 3.13% | 51.09万 | 4.16亿 | | 300253 | 卫宁健康 | 10.70 | 2.79% | 116.23万 | 12.39亿 | | 688222 | 成都先导 | 23.03 | 2.54% | 23.20万 | 5.33亿 | | 603990 | 麦迪科技 | 15 ...